McKenna Mark C.'s Form 4 filing
Prometheus Biosciences, Inc. (RXDX) · filed Mar 17, 2023
- Accession no.
- 0001209191-23-019948
- Filed
- Mar 17, 2023
- Trade date
- Mar 15, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.90M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McKenna Mark C.CIK 0001749623 | Director, Officer (Chairman, President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2023 | Common Stock | MOption exerciseAcquired | +25,000 | $2.90 | +$72,500 | 80,144 | Direct | |
| Mar 15, 2023 | Common Stock | SSaleDisposed | −25,000 | $116.14 | −$2,903,500 | 55,144 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2023 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 283,633 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.